A Phase 1/2 interventional study of MSC-Derived Exosomes and Platelet-rich fibrin (PRF) in Alveolar Bone Loss, Tooth Extraction and Bone Regeneration, sponsored by Al Salam University. Recruiting at 1 site in Egypt. Open to participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-02.
Sponsored by Al Salam University · Phase 1/2, Interventional, and Treatment
How we know · 3 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Alveolar Bone Loss with a site in Egypt — 22 open to participants now, 27 under way, none of them phase 3. Alveolar Bone Loss · Egypt.
Among the 75 studies in Alveolar Bone Loss with a site in Egypt, this one is the 8th largest by planned enrollment of the 74 interventional ones that give a count, is one of 9 that started in 2026, is the only one in phase 1/2, reaches primary completion later than 14 of the 26 other live ones, and was the 62nd registered.
320 studies on the registry are indexed under Alveolar Bone Loss; 79 are open to participants now.
Browse Alveolar Bone Loss studies →22 of the 75 studies in Alveolar Bone Loss with a site in Egypt are open now. Recruiting first, the newest first:
Horus University · Sites in Egypt
Ages 25–35 · Healthy volunteers
Beni-Suef University · Sites in Egypt
Ages 20–75 · Healthy volunteers
Future University in Egypt · Sites in Egypt
Ages 20–50
Basma Gamal Mohamed Ahmed · Sites in Egypt
British University In Egypt · Sites in Egypt
Ages 18–65 · Healthy volunteers
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 47 Alveolar Bone Loss studies recruiting now, 19 (40%) set no upper age limit and 22 (47%) stop at 75 or younger; 4 take children under 18; 24 take healthy volunteers.
This study: 20 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 1 · Phase 4 2
First in 2018; this study’s year is marked. 9 started in 2026.
This study's planned enrollment of 40 is above the median of 25 across 271 interventional studies indexed under Alveolar Bone Loss.
Median enrollment 20 across the 74 interventional studies, 23 across the 1 observational. Of the 37 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 75 has an industry lead sponsor. The 10 most frequent:
Al Salam University is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Al Salam University has 1 study filed under Alveolar Bone Loss — fewer than ten, so there is no comparison to draw.
6 of the studies in Alveolar Bone Loss with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07475507Cairo UniversityEffect of PEEK and Titanium Framework Reinforcement on Marginal Bone Loss Around Implants Supporting a Fixed All-on-four Prosthesis in Completely Edentulous Mandibles | 2026-12 |
| NCT07701473Cairo UniversityNovel Synthetic Membrane for Horizontal Bone Augmentation: A Case Series | 2027-03-01 |
| NCT06313229Kafrelsheikh UniversitySimultaneous Implant Placement With Vertical and Horizontal Bone Augmentation | 2027-04-30 |
| NCT07841158Mohammed Mahmoud AbedHistological and Histomorphometric Assessment With Inflammatory Profile Analysis of Bone Tissue After Horizontal Ridge Augmentation Using Customized Porous Zirconia Shell | 2027-05-01 |
| NCT07869030Future University in EgyptMelatonin Effect on Immediate Dental Implants in the Posterior Mandible | 2027-06 |
Add all 6 to your calendar (.ics) → With an account.
Among the 75 studies in Alveolar Bone Loss with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates two different treatments used to help the jawbone heal after a tooth is removed. When a tooth is extracted, the surrounding bone often shrinks, which can make it difficult to place dental implants later. Currently, doctors often use Platelet-Rich Fibrin (PRF), which is made from the patient's own blood, to help the area heal.
This research compares PRF to a newer treatment using "exosomes" derived from stem cells. Exosomes are tiny particles that carry signals to tell the body to repair tissue and grow new bone. The goal of this study is to see if these exosomes work better than PRF at keeping the bone strong and thick after an extraction. Researchers will use specialized X-rays (CBCT) to measure the bone three months after the procedure to see which treatment provided better results.
This is a randomized, single-blind, controlled clinical trial designed to compare the regenerative potential of Mesenchymal Stem Cell (MSC)-derived exosomes versus Autologous Platelet-Rich Fibrin (PRF) in alveolar ridge preservation.
A total of 40 patients requiring a single non-infected tooth extraction in the aesthetic zone or premolar area are enrolled and randomized into two equal groups (n=20).
Group A (Intervention): Following atraumatic extraction, MSC-derived exosomes are applied to the extraction socket.
Group B (Control): Following atraumatic extraction, autologous PRF (prepared via centrifugation) is placed in the socket.
The primary outcome measure is the change in alveolar bone density (measured in Hounsfield Units) and ridge dimensions (width and height) using Cone Beam Computed Tomography (CBCT) at baseline and 3 months post-operatively. Secondary outcomes include the assessment of soft tissue healing using the Landry Index, and patient-reported outcomes including postoperative pain (Visual Analog Scale) and swelling. The study aims to determine if the cell-free approach of exosome therapy provides a more standardized and effective alternative to traditional PRF for ridge preservation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in this group will receive Mesenchymal Stem Cell (MSC)-derived exosomes placed into the extraction socket immediately following tooth removal.
Biological: MSC-Derived Exosomes
Patients in this group will receive autologous Platelet-Rich Fibrin (PRF) placed into the extraction socket immediately following tooth removal.
Biological: Platelet-rich fibrin (PRF)
A cell-free regenerative therapy consisting of purified exosomes derived from mesenchymal stem cells, applied to promote bone healing and reduce ridge resorption.
A second-generation platelet concentrate prepared by centrifuging the patient's own blood at the time of surgery to create a fibrin clot rich in growth factors.
Change in Alveolar Bone Density (Hounsfield Units)
Bone density will be measured using Cone Beam Computed Tomography (CBCT). The mean Hounsfield Units (HU) will be calculated in the center of the extraction socket to evaluate the quality of new bone formation.
Time frame: Baseline (Day of surgery) and 3 months post-operatively.
Alveolar Ridge Dimensional Changes (Height and Width)
The horizontal width and vertical height of the alveolar ridge will be measured in millimeters (mm) using standardized cross-sectional CBCT images to assess the amount of bone resorption or preservation.
Time frame: Baseline (Day of surgery) and 3 months post-operatively.
Soft Tissue Healing Score (Landry Index)
Clinical assessment of the surgical site using the Landry, Turnbull, and Heasman Index. The scale ranges from 1 (very poor) to 5 (excellent) based on tissue color, response to palpation, and presence of granulation tissue.
Time frame: 7 days and 14 days post-operatively.
Patient-Reported Postoperative Pain (VAS Score)
Pain levels will be self-reported by patients using a Visual Analog Scale (VAS) ranging from 0 (no pain) to 10 (worst imaginable pain).
Time frame: Daily for the first 7 days post-operatively.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Individual participant data (IPD) will not be shared to protect the intellectual property of the research prior to official publication. Furthermore, the informed consent provided by the participants did not include a provision for the public sharing of raw individual data, ensuring the maintenance of patient confidentiality and privacy according to institutional ethics committee guidelines.
Started Jan 2026 (actual). Primary completion is estimated for Jul 2026, 6 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Al Salam University